| Dr Philip Alan Hess, MD | |
|
334 Town Center Ave, Big Sky, MT 59716 | |
| (406) 995-6995 | |
| Not Available |
| Full Name | Dr Philip Alan Hess |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 29 Years |
| Location | 334 Town Center Ave, Big Sky, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114028735 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 6474 (Alaska) | Secondary |
| 207Q00000X | Family Medicine | 40946 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Broadwater Health Center | Townsend, MT | Hospital |
| Wheatland Memorial Hospital | Harlowton, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Townsend Health Systems Inc | 7214845817 | 11 |
| Wheatland Memorial Healthcare | 3375451370 | 11 |
News Archive
Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.
Decades of painstaking research has yielded the most in-depth look ever at the management of bowel stricture recurrence in patients who undergo surgery for Crohn's disease. The findings should provide much-needed guidance to surgeons and gastroenterologists battling this tough-to-manage intestinal disorder.
In the daunting marathon that leads to successful drugs, promising drug candidates must pass toxicity tests before entering clinical trials.
World-renowned evolutionary biologist David Reznick is the author of "The Origin Then and Now: An Interpretive Guide to the Origin of Species" (Princeton University Press, 2009), which makes Darwin's book (hereafter "the Origin") more accessible by explaining its historical context, and converting it into more modern terms. Reznick's book also explains the immediate and longer term impacts of the Origin.
› Verified 6 days ago
| Entity Name | St. Peter's Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205025145 PECOS PAC ID: 7911814926 Enrollment ID: O20031204001245 |
News Archive
Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.
Decades of painstaking research has yielded the most in-depth look ever at the management of bowel stricture recurrence in patients who undergo surgery for Crohn's disease. The findings should provide much-needed guidance to surgeons and gastroenterologists battling this tough-to-manage intestinal disorder.
In the daunting marathon that leads to successful drugs, promising drug candidates must pass toxicity tests before entering clinical trials.
World-renowned evolutionary biologist David Reznick is the author of "The Origin Then and Now: An Interpretive Guide to the Origin of Species" (Princeton University Press, 2009), which makes Darwin's book (hereafter "the Origin") more accessible by explaining its historical context, and converting it into more modern terms. Reznick's book also explains the immediate and longer term impacts of the Origin.
› Verified 6 days ago
| Entity Name | Community Health Partners Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487741005 PECOS PAC ID: 5799681482 Enrollment ID: O20031211001095 |
News Archive
Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.
Decades of painstaking research has yielded the most in-depth look ever at the management of bowel stricture recurrence in patients who undergo surgery for Crohn's disease. The findings should provide much-needed guidance to surgeons and gastroenterologists battling this tough-to-manage intestinal disorder.
In the daunting marathon that leads to successful drugs, promising drug candidates must pass toxicity tests before entering clinical trials.
World-renowned evolutionary biologist David Reznick is the author of "The Origin Then and Now: An Interpretive Guide to the Origin of Species" (Princeton University Press, 2009), which makes Darwin's book (hereafter "the Origin") more accessible by explaining its historical context, and converting it into more modern terms. Reznick's book also explains the immediate and longer term impacts of the Origin.
› Verified 6 days ago
| Entity Name | Townsend Health Systems Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447245857 PECOS PAC ID: 7214845817 Enrollment ID: O20031223000506 |
News Archive
Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.
Decades of painstaking research has yielded the most in-depth look ever at the management of bowel stricture recurrence in patients who undergo surgery for Crohn's disease. The findings should provide much-needed guidance to surgeons and gastroenterologists battling this tough-to-manage intestinal disorder.
In the daunting marathon that leads to successful drugs, promising drug candidates must pass toxicity tests before entering clinical trials.
World-renowned evolutionary biologist David Reznick is the author of "The Origin Then and Now: An Interpretive Guide to the Origin of Species" (Princeton University Press, 2009), which makes Darwin's book (hereafter "the Origin") more accessible by explaining its historical context, and converting it into more modern terms. Reznick's book also explains the immediate and longer term impacts of the Origin.
› Verified 6 days ago
| Entity Name | Wheatland Memorial Healthcare |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235204538 PECOS PAC ID: 3375451370 Enrollment ID: O20040120000523 |
News Archive
Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.
Decades of painstaking research has yielded the most in-depth look ever at the management of bowel stricture recurrence in patients who undergo surgery for Crohn's disease. The findings should provide much-needed guidance to surgeons and gastroenterologists battling this tough-to-manage intestinal disorder.
In the daunting marathon that leads to successful drugs, promising drug candidates must pass toxicity tests before entering clinical trials.
World-renowned evolutionary biologist David Reznick is the author of "The Origin Then and Now: An Interpretive Guide to the Origin of Species" (Princeton University Press, 2009), which makes Darwin's book (hereafter "the Origin") more accessible by explaining its historical context, and converting it into more modern terms. Reznick's book also explains the immediate and longer term impacts of the Origin.
› Verified 6 days ago
| Entity Name | Townsend Health Systems Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1447245857 PECOS PAC ID: 7214845817 Enrollment ID: O20061104000088 |
News Archive
Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.
Decades of painstaking research has yielded the most in-depth look ever at the management of bowel stricture recurrence in patients who undergo surgery for Crohn's disease. The findings should provide much-needed guidance to surgeons and gastroenterologists battling this tough-to-manage intestinal disorder.
In the daunting marathon that leads to successful drugs, promising drug candidates must pass toxicity tests before entering clinical trials.
World-renowned evolutionary biologist David Reznick is the author of "The Origin Then and Now: An Interpretive Guide to the Origin of Species" (Princeton University Press, 2009), which makes Darwin's book (hereafter "the Origin") more accessible by explaining its historical context, and converting it into more modern terms. Reznick's book also explains the immediate and longer term impacts of the Origin.
› Verified 6 days ago
| Entity Name | Billings Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326104845 PECOS PAC ID: 6002993516 Enrollment ID: O20080430000212 |
News Archive
Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.
Decades of painstaking research has yielded the most in-depth look ever at the management of bowel stricture recurrence in patients who undergo surgery for Crohn's disease. The findings should provide much-needed guidance to surgeons and gastroenterologists battling this tough-to-manage intestinal disorder.
In the daunting marathon that leads to successful drugs, promising drug candidates must pass toxicity tests before entering clinical trials.
World-renowned evolutionary biologist David Reznick is the author of "The Origin Then and Now: An Interpretive Guide to the Origin of Species" (Princeton University Press, 2009), which makes Darwin's book (hereafter "the Origin") more accessible by explaining its historical context, and converting it into more modern terms. Reznick's book also explains the immediate and longer term impacts of the Origin.
› Verified 6 days ago
| Entity Name | St. Peter's Health |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1033354683 PECOS PAC ID: 7911814926 Enrollment ID: O20090202000564 |
News Archive
Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.
Decades of painstaking research has yielded the most in-depth look ever at the management of bowel stricture recurrence in patients who undergo surgery for Crohn's disease. The findings should provide much-needed guidance to surgeons and gastroenterologists battling this tough-to-manage intestinal disorder.
In the daunting marathon that leads to successful drugs, promising drug candidates must pass toxicity tests before entering clinical trials.
World-renowned evolutionary biologist David Reznick is the author of "The Origin Then and Now: An Interpretive Guide to the Origin of Species" (Princeton University Press, 2009), which makes Darwin's book (hereafter "the Origin") more accessible by explaining its historical context, and converting it into more modern terms. Reznick's book also explains the immediate and longer term impacts of the Origin.
› Verified 6 days ago
| Entity Name | Bozeman Health Big Sky Medical Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740659952 PECOS PAC ID: 7315256872 Enrollment ID: O20151023000110 |
News Archive
Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.
Decades of painstaking research has yielded the most in-depth look ever at the management of bowel stricture recurrence in patients who undergo surgery for Crohn's disease. The findings should provide much-needed guidance to surgeons and gastroenterologists battling this tough-to-manage intestinal disorder.
In the daunting marathon that leads to successful drugs, promising drug candidates must pass toxicity tests before entering clinical trials.
World-renowned evolutionary biologist David Reznick is the author of "The Origin Then and Now: An Interpretive Guide to the Origin of Species" (Princeton University Press, 2009), which makes Darwin's book (hereafter "the Origin") more accessible by explaining its historical context, and converting it into more modern terms. Reznick's book also explains the immediate and longer term impacts of the Origin.
› Verified 6 days ago
| Entity Name | Bozeman Health Big Sky Medical Center Llc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1588141048 PECOS PAC ID: 7315256872 Enrollment ID: O20181114003365 |
News Archive
Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.
Decades of painstaking research has yielded the most in-depth look ever at the management of bowel stricture recurrence in patients who undergo surgery for Crohn's disease. The findings should provide much-needed guidance to surgeons and gastroenterologists battling this tough-to-manage intestinal disorder.
In the daunting marathon that leads to successful drugs, promising drug candidates must pass toxicity tests before entering clinical trials.
World-renowned evolutionary biologist David Reznick is the author of "The Origin Then and Now: An Interpretive Guide to the Origin of Species" (Princeton University Press, 2009), which makes Darwin's book (hereafter "the Origin") more accessible by explaining its historical context, and converting it into more modern terms. Reznick's book also explains the immediate and longer term impacts of the Origin.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Philip Alan Hess, MD 110 N Oak St, Townsend, MT 59644-2306 Ph: (406) 266-3186 | Dr Philip Alan Hess, MD 334 Town Center Ave, Big Sky, MT 59716 Ph: (406) 995-6995 |
News Archive
Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.
Decades of painstaking research has yielded the most in-depth look ever at the management of bowel stricture recurrence in patients who undergo surgery for Crohn's disease. The findings should provide much-needed guidance to surgeons and gastroenterologists battling this tough-to-manage intestinal disorder.
In the daunting marathon that leads to successful drugs, promising drug candidates must pass toxicity tests before entering clinical trials.
World-renowned evolutionary biologist David Reznick is the author of "The Origin Then and Now: An Interpretive Guide to the Origin of Species" (Princeton University Press, 2009), which makes Darwin's book (hereafter "the Origin") more accessible by explaining its historical context, and converting it into more modern terms. Reznick's book also explains the immediate and longer term impacts of the Origin.
› Verified 6 days ago
Ms. Maren J Dunn Chandler, DO Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 334 Town Center Ave, Big Sky, MT 59716 Phone: 406-995-6995 | |
Dr. Lehman Clark Sammons Jr., MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 100 Beaverhead Trail, Big Sky, MT 59716 Phone: 406-993-2797 Fax: 406-995-2965 | |
Kevin Curtis Sullivan, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 334 Town Center Ave, Big Sky, MT 59715 Phone: 406-995-6995 | |
Jeremy Philip Mitchell, DO Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 334 Town Center Ave, Big Sky, MT 59716 Phone: 406-995-6995 |